Terms: = Lung cancer AND CD74, ENSG00000019582, 972, protein 41, Ia-GAMMA, HLADG, DHLAG AND Treatment
97 results:
1. Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III non-small-cell lung cancer: Results from the phase 1 CLOVER study.
Kim DW; Chul Cho B; Pachipala K; Kim SW; Wang CL; Chang GC; Ahn MJ; Alvarez R; Chiu CH; Trigo J; Estival A; Karam SD; O'Brien C; Gowda H; Jiang H; Bauman JE
Lung Cancer; 2024 Apr; 190():107530. PubMed ID: 38471416
[TBL] [Abstract] [Full Text] [Related]
2. Mechanisms of Resistance to Tyrosine Kinase Inhibitors in ROS1 Fusion-Positive Nonsmall Cell lung cancer.
Zhao X; Zhang X; Chen H; Bao H; Wu X; Wang H; Bao H; Pang J; Wang S; Wang J
Clin Chem; 2024 Apr; 70(4):629-641. PubMed ID: 38416709
[TBL] [Abstract] [Full Text] [Related]
3. cd74-ROS1 L2026M mutant enhances autophagy through the MEK/ERK pathway to promote invasion, metastasis and crizotinib resistance in non-small cell lung cancer cells.
Xu X; Li Y; Xu R; Meng Y; Li Z; Zuo D; Wu Y
FEBS J; 2024 Mar; 291(6):1199-1219. PubMed ID: 38148635
[TBL] [Abstract] [Full Text] [Related]
4. The Association between ER, PR, HER2, and ER-/PR+ Expression and lung cancer Subsequent in Breast cancer Patients: A Retrospective Cohort Study Based on SEER Database.
Shao HY; Hao BT; Gao FX
Breast J; 2023; 2023():7028189. PubMed ID: 38021219
[TBL] [Abstract] [Full Text] [Related]
5. Association of antibiotic exposure with survival in patients with extensive-stage small cell lung cancer receiving immune checkpoint inhibitor therapy.
Zhong J; Xiong D; Liu Y; Yuan S
Thorac Cancer; 2024 Jan; 15(2):152-162. PubMed ID: 38010059
[TBL] [Abstract] [Full Text] [Related]
6. Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON).
Garon EB; Cho BC; Luft A; Alatorre-Alexander J; Geater SL; Kim SW; Ursol G; Hussein M; Lim FL; Yang CT; Araujo LH; Saito H; Reinmuth N; Medic N; Mann H; Shi X; Peters S; Mok T; Johnson M
Lung Cancer; 2023 Dec; 186():107422. PubMed ID: 37992595
[TBL] [Abstract] [Full Text] [Related]
7. A case of cd74-ROS1-positive lung adenocarcinoma diagnosed by next-generation sequencing achieved long-term survival with pemetrexed regimens.
Tanaka S; Yoshimura N; Asakawa R; Tobita S; Yaga M; Ueno K
Thorac Cancer; 2023 Sep; 14(25):2618-2621. PubMed ID: 37488715
[TBL] [Abstract] [Full Text] [Related]
8. Next Generation Sequencing Analysis and its Benefit for Targeted Therapy of lung Adenocarcinoma.
Kulda V; Polivka J; Svaton M; Vanecek T; Buresova M; Houfkova K; Bagheri MS; Knizkova T; Vankova B; Windrichova J; Macan P; Babuska V; Pesta M
Cancer Genomics Proteomics; 2023; 20(4):404-411. PubMed ID: 37400146
[TBL] [Abstract] [Full Text] [Related]
9. Discovery of novel 2-aminopyridine derivatives as ROS1 and ALK dual inhibitors to combat drug-resistant mutants including ROS1
Liu S; Huang C; Huang C; Huang Y; Yu Y; Wu G; Guo F; Jiang Y; Wan S; Zhu Z; Tian Y; Zhu J; Zhang J
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2227779. PubMed ID: 37349867
[TBL] [Abstract] [Full Text] [Related]
10. Prognostic role of cd74, CD10 and Ki-67 immunohistochemical expression in patients with diffuse malignant peritoneal mesothelioma: a retrospective study.
Liang Y; Li C; Liu Y; Tian L; Yang D
BMC Cancer; 2023 May; 23(1):406. PubMed ID: 37147569
[TBL] [Abstract] [Full Text] [Related]
11. High-resolution single-cell atlas reveals diversity and plasticity of tissue-resident neutrophils in non-small cell lung cancer.
Salcher S; Sturm G; Horvath L; Untergasser G; Kuempers C; Fotakis G; Panizzolo E; Martowicz A; Trebo M; Pall G; Gamerith G; Sykora M; Augustin F; Schmitz K; Finotello F; Rieder D; Perner S; Sopper S; Wolf D; Pircher A; Trajanoski Z
Cancer Cell; 2022 Dec; 40(12):1503-1520.e8. PubMed ID: 36368318
[TBL] [Abstract] [Full Text] [Related]
12. Construction of crizotinib resistant models with cd74-ROS1 D2033N and cd74-ROS1 S1986F point mutations to explore resistance mechanism and treatment strategy.
Sun R; Meng Y; Xu R; Li Y; Xu X; Li Z; Zuo D
Cell Signal; 2023 Jan; 101():110497. PubMed ID: 36265718
[TBL] [Abstract] [Full Text] [Related]
13. MET gene amplification is a mechanism of resistance to entrectinib in ROS1+ NSCLC.
Tyler LC; Le AT; Chen N; Nijmeh H; Bao L; Wilson TR; Chen D; Simmons B; Turner KM; Perusse D; Kasibhatla S; Christiansen J; Dudek AZ; Doebele RC
Thorac Cancer; 2022 Nov; 13(21):3032-3041. PubMed ID: 36101520
[TBL] [Abstract] [Full Text] [Related]
14. A case of multiple primary lung adenocarcinoma with a cd74-NRG1 fusion protein and HER2 mutation benefit from combined target therapy.
Chen K; Li W; Xi X; Zhong J
Thorac Cancer; 2022 Nov; 13(21):3063-3067. PubMed ID: 36096509
[TBL] [Abstract] [Full Text] [Related]
15. Geriatric Nutritional Risk Index as a Prognostic Factor of Patients with Non-Small Cell lung cancer: A Meta-Analysis.
Yang M; Liu Z; Li G; Li B; Li C; Xiao L; Zhou J
Horm Metab Res; 2022 Sep; 54(9):604-612. PubMed ID: 36070746
[TBL] [Abstract] [Full Text] [Related]
16. Predictors of Survival in Favorable Risk Patients with Metastatic Renal Cell Carcinoma Treated with a Single-Agent First-Line Therapy.
Mizuno R; Takamatsu K; Yasumizu Y; Tanaka N; Takeda T; Morita S; Matsumoto K; Kosaka T; Asanuma H; Mikami S; Oya M
Urol Int; 2022; 106(11):1145-1149. PubMed ID: 35139522
[TBL] [Abstract] [Full Text] [Related]
17. Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements.
Schram AM; Odintsov I; Espinosa-Cotton M; Khodos I; Sisso WJ; Mattar MS; Lui AJW; Vojnic M; Shameem SH; Chauhan T; Torrisi J; Ford J; O'Connor MN; Geuijen CAW; Schackmann RCJ; Lammerts van Bueren JJ; Wasserman E; de Stanchina E; O'Reilly EM; Ladanyi M; Drilon A; Somwar R
Cancer Discov; 2022 May; 12(5):1233-1247. PubMed ID: 35135829
[TBL] [Abstract] [Full Text] [Related]
18. Inflammation-scores as prognostic markers of overall survival in lung cancer: a register-based study of 6,210 Danish lung cancer patients.
Winther-Larsen A; Aggerholm-Pedersen N; Sandfeld-Paulsen B
BMC Cancer; 2022 Jan; 22(1):63. PubMed ID: 35027001
[TBL] [Abstract] [Full Text] [Related]
19. Effect of almonertinib on the proliferation, invasion, and migration in non-small cell lung cancer cells.
Zhang Y; Zhang Y; Niu W; Ge X; Li X; Fan F; Li S; Liu H
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Oct; 46(10):1045-1053. PubMed ID: 34911833
[TBL] [Abstract] [Full Text] [Related]
20. Resistance Profile and Structural Modeling of Next-Generation ROS1 Tyrosine Kinase Inhibitors.
Keddy C; Shinde P; Jones K; Kaech S; Somwar R; Shinde U; Davare MA
Mol Cancer Ther; 2022 Feb; 21(2):336-346. PubMed ID: 34907086
[TBL] [Abstract] [Full Text] [Related]
[Next]
